New biologics for food allergy

Area of Science:

• Immunology
• Allergology
• Pharmacology

Background:

• Food allergy is a growing global health concern with limited effective treatments.
• Current management strategies, including oral immunotherapy (OIT), face challenges with adverse events and efficacy.
• Biologics represent a novel therapeutic avenue for managing food allergies.

Purpose of the Study:

• To review the role of emerging biologics in food allergy management.
• To evaluate the potential of specific biologics (ligelizumab, UB-221, dupilumab, antialarmins) in improving OIT and reducing allergic reactions.
• To discuss the limitations of current therapies and the promise of new biologic agents.

Main Methods:

• Literature review of recent studies on biologics in food allergy.
• Analysis of clinical trial data for agents like ligelizumab, UB-221, dupilumab, etokimab, and tezepelumab.
• Evaluation of mechanisms of action and efficacy in preclinical and clinical settings.

Main Results:

• Anti-immunoglobulin E (IgE) monoclonal antibodies (mAbs) like omalizumab improve OIT safety.
• Next-generation anti-IgE antibodies (ligelizumab, UB-221) demonstrate enhanced potency.
• Dupilumab shows potential for modifying the atopic march, and antialarmins (etokimab, tezepelumab) show early promise.

Conclusions:

• Biologics offer significant potential for advancing food allergy treatment.
• Personalized treatment approaches, considering patient preferences and shared decision-making, are crucial.
• The evolving landscape of biologics provides allergists with expanded therapeutic options for food allergy management.